Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 9/20 | 0.56 |
| ▸ | CTSS | P25774 | 5/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | TACR2 | P21452 | 3/20 | 0.48 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.47 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.47 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.47 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.47 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.47 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.47 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.47 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.47 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.47 |
| ▸ | PSMB3 | P49720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7345737 | 0.87 | CACNA1B (0.62) | CACNA1BCTSSCTSLCTSKPSMB11 | |
| SCHEMBL7339817 | 0.87 | CACNA1B (0.62) | CACNA1BCTSSCTSLCTSKPSMB11 | |
| SCHEMBL7345251 | 0.87 | TACR2 (0.60) | CACNA1BCTSSTACR2PSMB11PSMA7 | |
| SCHEMBL7547524 | 0.86 | GAA (0.52) | CTSSCTSLCTSKTACR2 | |
| SCHEMBL7343211 | 0.84 | CACNA1B (0.59) | CACNA1BCTSSCTSLCTSKPSMB11 | |
| SCHEMBL7480901 | 0.84 | CACNA1B (0.58) | CACNA1BCTSSCTSLCTSKPSMB11 | |
| SCHEMBL7963499 | 0.84 | CACNA1B (0.61) | CACNA1BCTSSCTSLCTSKPSMB11 | |
| SCHEMBL7547062 | 0.84 | CACNA1B (0.57) | CACNA1BCTSSCTSLCTSKPSMB11 | |
| SCHEMBL7342593 | 0.83 | TACR2 (0.58) | CACNA1BCTSSTACR2PSMB11PSMA7 | |
| SCHEMBL7543753 | 0.83 | GAA (0.49) | CTSSCTSLCTSKTACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000006559-A1 | REDUCED DIPEPTIDE ANALOGUES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2000-02-10 | — | — | WO | claimed |
| US-6362174-B1 | ANALGESICS, ANTIISCHEMIC AGENTS, ANTIEOILEPTIC AGENTS | WARNER-LAMBERT COMPANY | 2002-03-26 | — | — | US | disclosed |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | RAFFERTY MICHAEL FRANCIS (US) | 2002-03-07 | — | — | US | disclosed |
| US-6316440-B1 | TREATMENT OF STROKE, HEAD TRAUMA, CEREBRAL ISCHEMIA, PAIN AND EPILEPSY | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | CACNA1E, RYR1, CACNA1B | CACNA1B 3/4885CTSS 2158/4885CTSL 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.